[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Mr Biden and Dr Fauci and EU difficulties", "description": "UK\nhttps://coronavirus.data.gov.uk/details/cases\n\nCases, + 6,391 (+53,761)\nDown 29.4%\n\nHospital admissions, + 1,110 (+ 8,463)\nDown 22.1%\n\nDeaths, + 343 (+1,991)\nDown 36%\n\nVaccine, first dose, 20,478,619\n\nSecond dose, 844,098\n\nUS\n\nhttps://www.bbc.co.uk/news/world-us-canada-56262687\n\nPresident Biden\n\nEnough vaccines for every adult by the end of May\n\nTwo months earlier than expected\n\n100 in 100 well on track\n\nAbout 1.74 million per day\n\nMerck now helping Johnson & Johnson\n\nWe're now on track to have enough vaccine supply for every adult in America by the end of May\n\nthe type of collaboration between companies we saw in World War Two\n\nStay vigilant\n\nthis fight is far from over\n\nVOCs\n\nWe cannot let our guard down now or assure that victory is inevitable\n\nWe can't assume that\n\nVaccines for children\n\nhttps://www.nbcnews.com/meet-the-press/meet-press-february-28-2021-n1259095\n\nDr. Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases\n\nChildren under 12 years very likely, end of 2021 or beginning of 2022\n\nBased on, \n\nIf you project realistically when we'll get enough data to be able to say that elementary school children will be able to be vaccinated, I would think that would be, at the earliest, the end of the year, and very likely, the first quarter of 2022\n \nHigh school students will likely be able to get vaccinated this fall\n\nCloser to herd immunity\n\nEncouraged Americans to continue to wear face masks, avoid crowds, and follow social distancing guidelines\n\nyou've got to get that baseline down lower than it is now\n\nVOCs emerging in California and New York\n\nTexas\n\nGov. Greg Abbott\n\nhttps://www.chron.com/news/houston-texas/article/mask-mandate-ends-business-open-15994001.php\n\nEnd of the state wide mask mandate\n\nBusinesses can open at 100% capacity March 10\n\nstate mandates are no longer needed\n\nMississippi \n\nRemoving the order on mask wearing, today\n\nMichigan,\n\nEasing capacity limits on restaurants, public and residential gatherings\n\nSouth Carolina, Massachusetts, Chicago \n\nSan Francisco\n\nEasing of rules on museums, cinemas, gyms and indoor dining\n\nEU\n\nhttps://www.telegraph.co.uk/news/2021/03/02/eu-unity-face-coronavirus-pressure-vaccines-supplies/\n\nAustria, Chancellor Sebastian Kurz\n\nAustria would work with Israel and Denmark on second generation vaccines\n\nno longer rely on the EU in the future\n\nEuropean Medicines Agency, too slow\n\nWe must therefore prepare for further mutations and should no longer be dependent only on the EU for the production of second-generation vaccines\n\nDenmark Prime Minister Mette Frederiksen\n\nBid for supplies of Israel\u2019s leftover vaccines\n\nMr Kurz and Ms Frederiksen going to Israel\n\nPoland\n\nTalking to China about supplies\n\n\nSlovakia\n\nTwo million doses of the Sputnik delivered (not been approved by the European Medicines Agency)\n\nCzech\n\nDue to buy Sputnik\n\nHungary\n\nAlready approved and bought 2 million doses of Sputnik \n\nViktor Orb\u00e1n, photo of himself being vaccinated by the Chinese Sinopharm vaccine (5 million doses)\n\nWe\u2019ve sought to do something together that we could have managed more successfully on an individual basis \u2013 take a look at the examples of Britain or Serbia\n\n\nFrance\n\nRegional leaders trying to negotiate directly with pharmaceutical suppliers\n\nGermany\n\nOrdered 30 million extra doses of the Pfizer and 20m doses with CureVac\n\nUrsula von der Leyen\n\nWe have all agreed that there will be no parallel negotiations or parallel contracts \n\nMalta\n\nPopulation 502,000\n\nhttps://deputyprimeminister.gov.mt/en/health-promotion/covid-19/Pages/covid-19-infographics.aspx\n\nItaly\n\nOxford Astra Zeneca, not given to over 65 years old nor to people with any disease/health condition\n\nCurrently it seems like I\u00b4ll have to wait at least a year for my vaccination\n\nSpain\n\nhttp://www.surinenglish.com/national/202103/02/spain-ministry-health-recommends-20210302190600.html\n\nOxford AZ only being used in under 55s\n\nAdvise, 1g paracetamol before and for every 6 hours after vaccination if minor side effects appear\n\nWHO\n\nhttps://www.youtube.com/watch?v=NeDeOxb4ofg\n\nhttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/press-briefings\n\nFirst, there is no reason for measures that unnecessarily interfere with international travel and trade. WHO doesn\u2019t recommend limiting trade and movement.", "link": "https://www.youtube.com/watch?v=KERAhqCD08E", "date_published": "2021-03-03 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Both UK vaccines working", "description": "https://www.gov.uk/government/news/new-data-show-vaccines-reduce-severe-covid-19-in-older-adults\n\nEarly effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in the UK: a test negative case control study\n \nhttps://khub.net/documents/135939561/430986542/Early+effectiveness+of+COVID+vaccines.pdf/ffd7161c-b255-8e88-c2dc-88979fc2cc1b?t=1614617945615\n\nObjectives\n\nReal-world effectiveness of the Pfizer/BioNTech BNT162b2 vaccine and \u2026\n\nAstrazeneca ChAdOx1 vaccine against\u2026.\n\nConfirmed COVID-19, hospitalisations and deaths\n\nTo estimate effectiveness on the UK variant of concern. \n\nSetting \n\nCommunity COVID-19 PCR testing in England \n\n8th December 2020 and 19th February 2021\n\nAll adults in England aged 70 years and older (over 7.5 million)\n\nAll symptomatic COVID-19 testing in the community in over 70s\n\nTest negative case control design \n\n174,731 PCR tests\n\n156,930 of these (89.8%) linked to vaccination data\n\n44,590 (28.4%) were positive tests\n\n112,340 (71.6%) were negative\n\nInterventions \n\nOne and two doses of BNT162b2 vaccine\n\nOne dose of ChAdOx1 vaccine\n\nMain outcome measures \n\nSymptomatic PCR confirmed SARS-CoV-2 infection\n\nHospitalisations and deaths with COVID-19. \n\nSymptomatic disease infection risk Results \n\nIndividuals aged more than 80 years vaccinated with Pfizer BNT162b2\n\nHigher odds of testing positive in the first 9 days after vaccination (odds ratio up to 1.48)\n\nVaccine effects were noted from 10-13 days after vaccination\n\nReaching an effectiveness of 70% from 28-34 days, then plateauing\n\nFrom 14 days after the second dose, vaccine effectiveness was 89%\n\n(Fewer than 10 over 80 sent to ITU every day in UK)\n\nIndividuals aged more than70 years\n\nPfizer BNT162b2\n\nVaccine effectiveness reached 61% from 28-34 days then plateaued \n\nAZ ChAdOx1\n\nVaccine effects, were seen from 14-20 days\n\nReaching an effectiveness of 60% from 28-34 days\n\nFurther increasing to 73% from day 35 onwards\n\nRisk of emergency hospitalisation and death results\n\nOne dose of BNT162b2\n\nAdditional 43% lower risk of emergency hospitalisation\n\nAdditional 51% lower risk of death\n\nOne dose of ChAdOx1\n\nAdditional 37% lower risk of emergency hospitalisation\n\nInsufficient follow-up to assess the effect of ChAdOx1 on mortality\n\nCombined with the effect against symptomatic disease\n\nSingle dose of either vaccine is approximately 80% effective at preventing hospitalisation\n\nSingle dose of BNT162b2 is 85% effective at preventing death\n\nSingle dose of ChAdOx1 unknown protective effect against death\n\nConclusion \n\nSignificant reduction in symptomatic SARS-CoV2 positive cases in older adults\n\nEven greater protection against severe disease\n\nBoth vaccines show similar effects\n\nProtection was maintained for more than 6 weeks\n\nA second dose of BNT162b2 provides further protection against symptomatic disease\n\nSecond doses of ChAdOx1 have not yet been rolled out in England\n\nThere is a clear effect of the vaccines against the UK variant of concern\n\nProfessor Jonathan Van-Tam\n\nJoint Committee on Vaccination and Immunisation\n\nnot immunologically plausible the vaccine would work in younger age groups and not older ones.\n\nDr Mary Ramsay, PHE's head of immunisation, said it could.\n\nIf anything we would expect it to be a stronger protection from the vaccine\n\nLower down in the age range is that people's chances of being hospitalised and dying are much lower\n\nFrance \n\nOxford/AstraZeneca vaccine, can be given to people with underlying health conditions in the 65-74 age group\n\n1.1m doses in country\n\nGermany\n\nStill not giving the AstraZeneca to the over-65s\n\nNow under discussion\n\nLarge stocks of that vaccine waiting to be used\n\n(Belgium, Poland, Italy, Sweden)\n\nProfessor Andrew Pollard, Oxford Vaccine group\n\nFindings were stunning\n\n5,000 people dying every day in Europe, important to increase confidence in vaccines\n\ndisappointing in some senses\n\nreally high levels of protection\n\nsupport their decision making\n\nOxford vaccine distributed to low-income countries, Covax scheme", "link": "https://www.youtube.com/watch?v=U3otWaBrvEc", "date_published": "2021-03-02 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]